Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arvinas Holding Company (ARVN) has issued an update.
Arvinas, Inc. has appointed Dr. Noah Berkowitz as its new chief medical officer to spearhead the clinical development of its innovative PROTAC® protein degrader programs in the fields of oncology and neuroscience. With a solid track record of over 20 years in the pharmaceutical industry, Dr. Berkowitz brings valuable experience from his previous leadership role in hematology at Bristol-Myers Squibb. Concurrently, the company is preparing for a smooth transition as Dr. Ron Peck, the former chief medical officer, will remain on board until mid-April 2024 to assist with the handover before he departs to explore new ventures.
Find detailed analytics on ARVN stock on TipRanks’ Stock Analysis page.